Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S224-S228 , March 2004

Cyclosporine-Induced renal dysfunction

  • L.C Paul

      Affiliations

    • Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
    • Corresponding Author InformationAddress reprint requests to L.C. Paul, Department of Nephrology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
    • ,
  • J.H de Fijter

      Affiliations

    • Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

References 

  1. Gill JS, Tonelli M, Mix CH, et al.  The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol. 2003;14:1636
  2. National Kidney Foundation . K/DOQI clinical practise guidelines for chronic kidney disease (evaluation, classification, and stratification). Am J Kidney Dis. 2002;39(Suppl 1):S1
  3. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling (an evolution in effectiveness). Transplant Proc. 2000;32(Suppl 3A):45S
  4. Vercauteren SV, Bosmans JL, Elseviers MM, et al.  A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 1998;54:536
  5. Lidelow B, Bergh C-H, Herlitz H, et al.  Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol. 2000;11:951
  6. Ojo AO, Held PJ, Port FK, et al.  Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931
  7. Greenberg A, Thompson ME, Griffith BJ, et al.  Cyclosporine nephrotoxicity in cardiac allograft patients (seven year follow up). Transplantation. 1990;50:589
  8. Franceschini N, Alpers CE, Bennett WM, et al.  Cyclosporine arteriopathy (effects of drug withdrawal). Am J Kidney Dis. 1998;32:247
  9. Dimény E, Wahlberg J, Larsson E, et al.  Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection. Clin Transplant. 1995;9:79
  10. Isoniemi HM, Krogerus L, Von Willebrand E, et al.  Histopathological findings in well-functioning, long-term renal allografts. Kidney Int. 1992;41:155
  11. English J, Evan A, Houghton DC, et al.  Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987;44:135
  12. Cosio FG, Frankel WL, Pelletier RP, et al.  Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy (implications for graft survival). Am J Kidney Dis. 1999;34:731
  13. Dell'Antonio G, Randhawa PS. “Striped” pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Transplantation. 1999;67:484
  14. Abrass CK, Berfield AK, Stehman-Breen C, et al.  Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis. 1999;33:11
  15. Bakker RC, Koop K, Sijpkens YW, et al.  Early interstitial accumulation of collagen type I descriminates chronic rejection from chronic cyclosporine nephrotoxicity. J Am Soc Nephrol. 2003;14:2142
  16. Benigni A, Bruzzi I, Mister M, et al.  Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int. 1999;55:674
  17. Lafayette RA, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol. 1993;3:1892
  18. Andoh TF, Gardner MP, Bennett WM. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation. 1997;64:1236
  19. Kovarik JM, Mueller EA, Richard F, et al.  Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation. 1996;62:759
  20. Cole E, Maham N, Cardella C, et al.  Clinical benefit of neoral C2 monitoring in thelong-term management of renal transplant recipients. Transplantation. 2003;75:2086
  21. Toki K, Kyo M, Takahara S, et al.  Clinicopathological evaluation in non-episode biopsies of renal allograft. Transplant Int. 2000;13(Suppl 1):S73
  22. Cecka JM. The UNOS scientific renal transplant registry. In:  Cecka JM,  Terasaki PI editor. Clinical Transplants 1998. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1999;p. 1
  23. Hariharan S, Johnson CP, Bresnahan BA, et al.  Improved graft survival after transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605
  24. European Multicentre Trial Group Beveridge T, Calne RY. Cyclosporine (Sandimmune) in cadaveric renal transplantation (ten-year follow-up of a multicentre trial). Transplantation. 1995;59:1568
  25. European Multicentre Trial Group . European multicentre trial of cyclosporine in renal transplantation (10-year follow-up). Transplant Proc. 1993;25:527
  26. Ponticelli C, Civati G, Tarantino A, et al.  Randomized study with cyclosporine in kidney transplantation (10-year follow-up). J Am Soc Nephrol. 1996;7:792
  27. Burke JF, Pirsch JD, Ramos EL, et al.  Long-term efficacy and safety of cyclosporine in renal-transplant patients. N Engl J Med. 1994;331:358
  28. Kasiske BL, Chakkera HA, Louis TA, et al.  A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910
  29. Ivanyi B, Fahmy H, Brown H, et al: Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol 31:1129, 2000
  30. Mauiyyedi S, Della Pelle P, Saidman S, et al.  Identifying antibody mediated chronic renal allograft rejection by C4d in peritubular capillaries. J Am Soc Nephrol. 2001;12:574
  31. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int. 1995;48:S63
  32. Almond PS, Matas A, Gillingham KJ, et al.  Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752
  33. Kahan BD, Welsh M, Schoenberg L, et al.  Variable oral absorption of cyclosporine-A biopharmaceutical risk factor for chronic renal, allograft rejection. Transplantation. 1996;62:599
  34. Mihatsch MJ, Steiner K, Abeywickrama KH, et al.  Risk factors for the development of chronic cyclosporine-nephrotoxicity. Clin Nephrol. 1988;29:165
  35. Hill PA, Main IW, Atkins RC. ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int. 1995;47:1383
  36. Christians W, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem. 1995;28:547

PII: S0041-1345(04)00006-5

doi: 10.1016/j.transproceed.2004.01.005

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S224-S228 , March 2004

Article Tools